Role functioning before start of adjuvant treatment was an independent prognostic factor for survival and time to failure. A report from the Nordic adjuvant interferon trial for patients with high-risk melanoma

Acta Oncologica

Volumn 52, Issue 6, 2013, Pages 1086-1093

  Brandberg, Yvonne ^a   Johansson, Hemming ^a   Aamdal, Steinar ^b   Bastholt, Lars ^c   Hernberg, Michaela ^d   Stierner, Ulrika ^e   Von Der Maase, Hans ^f,g   Hansson, Johan ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b OSLO UNIVERSITY HOSPITAL   (Norway)

^c ODENSE UNIVERSITY HOSPITAL   (Denmark)

^d HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^e SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^f Copenhagen University Hospital ^*  (Denmark)

^g AARHUS UNIVERSITY HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

INTERFERON;

ADJUVANT THERAPY; ADULT; AGED; ARTICLE; CANCER PATIENT; CANCER PROGNOSIS; CANCER SURVIVAL; CONTROLLED STUDY; DENMARK; FATIGUE; FEMALE; FINLAND; HIGH RISK INFANT; HUMAN; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MELANOMA; MULTICENTER STUDY; NORWAY; PRIORITY JOURNAL; QUALITY OF LIFE; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; ROLE PLAYING; SOCIAL INTERACTION; SWEDEN; TREATMENT FAILURE; CANCER ADJUVANT THERAPY; CANCER SIZE; CANCER STAGING; COGNITION; DISEASE ASSOCIATION; DISEASE FREE SURVIVAL; DRUG MEGADOSE; HIGH RISK PATIENT; RANDOMIZED CONTROLLED TRIAL (TOPIC);

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC AGENTS; CHEMOTHERAPY, ADJUVANT; DISEASE-FREE SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; INTERFERONS; MALE; MELANOMA; MIDDLE AGED; PROGNOSIS; QUALITY OF LIFE; QUESTIONNAIRES; SKIN NEOPLASMS; YOUNG ADULT;

EID: 84880273462     PISSN: 0284186X     EISSN: 1651226X     Source Type: Journal    
DOI: 10.3109/0284186X.2013.789140     Document Type: Article

References (26)

1. Gotay CC, Kawamoto T, Bottomley A, Effi cace F. The prognostic signifi cance of patient-reported outcomes in cancer clinical trials. J Clin Oncol 2008; 26: 1355-63.
2. Sehlen S, Marten-Mittag B, Herschbach P, Schweden M, Book K, Henrich G, et al. Health-related quality of life supersedes other psychosocial predictors of long-term survival in cancer patients undergoing radiotherapy. Acta Oncol 2012; 51: 1020-8.
3. Montazeri A. Q uality of life data as prognostic indicators of survival in cancer patients: An overview of the literature from 1982 to 2008. Health Qual Life Outcomes 2009; 7: 102-23.
4. Cassileth BR L usk EJ, Miller DS, Brown LL, Miller C. Psychosocial correlates of survival in advanced malignant disease? N Engl J Med 1985; 312: 1551-5.
5. Cassileth BR, Walsh W P, Lusk E J. P sychosocial correlates of cancer survival: A subsequent report 3 to 8 years after cancer diagnosis. J Clin Oncol 1988; 6: 1753-9.
6. Coates A, Thomson D, McLeod G R, Hersey P, Gill P G, Olver IN, et al. Prognostic value of quality of life scores in a trial of chemotherapy with or without interferon in patients with metastatic malignant melanoma. Eur J Cancer 1993; 29: 1731-4.
7. Chiarion-Sileni V, Del Bianco P, D e Salvo GL, Lo Re G, Romanini A, Labianca R, et al. Quality of life evaluation in a randomized trial of chemotherapy versus bio-chemotherapy in advanced melanoma patients. Eur J Cancer 2003; 39: 1577-85.
8. Quinten C, Coens C, Mauer M, Comte S, Sprangers M A, Cleeland C, et al. Baseline quality of life as a prognostic indicator of survival: A meta-analysis of individual patient data from EORTC clinical trials. Lancet Oncol 2009; 10: 865-71.
9. Effi cace F, Therasse P, Piccart MJ, Coens C, van Steen K, Welnicka-Jaskiewicz M, et al. Health-related quality of life parameters as prognostic factors in a nonmetastatic breast cancer population: An international multicentre study. J Clin Oncol 2004; 22; 3381-8.
10. Goodwin PJ, Ennis M, Bordeleau LJ, Pritchard KI, Trudeau ME, Koo J, et al. Health-related quality of life and psychosocial status in breast cancer prognosis: Analysis of multiple variables. J Clin Oncol 2004; 22: 4184-92.
11. Osoba D, Slamon D J, Burchmore M, Murphy M. E ffects on quality of life of combined trastuzumab and chemotherapy in women with metastatic breast cancer. J Clin Oncol 2002; 20: 3106-13.
12. Brown JE, Butow PN, Culjak G, Coates AS, Dunn SM. Psychosocial predictors of outcome: Time to relapse and survival in patients with early stage melanoma. Br J Cancer 2000; 83: 1448-53.
13. Groenvold M, Petersen MA, Idler E, Bjorner JB, Fayers PM, Mouridsen HT. Psychosocial distress and fatigue predicted recurrence and survival in primary breast cancer patients. Br J Cancer 2007; 105: 209-19.
14. Effi cace F, Therasse P, Piccart MJ, Coens C, Van Steen K, Welnicka-Jaskiewicz M, et al. Health-related quality of life parameters as prognostic factors in a nonmetastatic breast cancer population: An international multicentre study. J Clin Oncol 2004; 22: 3381-8.
15. Hansson J, Aamdal S, Bastholt L, Brandberg Y, Hernberg M, Nilsson B, et al. Two different durations of adjuvant therapy with intermediate-dose interferon alfa-2b in patients with high-risk melanoma (Nordic IFN trial): A randomized phase 3 trial. Lancet Oncol 2011; 12: 144-52.
16. Brandberg Y, Aamdal S, Bastholt L, Hernberg M, Stierner U, von der Maase H, et al. Health-related quality of life in patients with high-risk melanoma randomised in the Nordic phase 3 trial with adjuvant intermediate-dose interferon alfa-2b. Eur J Cancer 2012; 48: 2012-9.
17. Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: A qualityof-life instrument for use in international clinical trials in oncology. J Nat Cancer Inst 1993; 85: 365-76.
18. Fayers P M, Aronson N K, Bjordal K, Groenvold M, Curran D, Bottomley A. The EORTC QLQ-C30 Scoring Manual, 3rd ed. Brussels: European Organization for Research and Treatment of Cancer; 2001.
19. Schemper M, Smith TL. A note on quantifying follow-up in studies of failure time. Control Clin Trials 1996; 17: 343-6.
20. Sauerbrei W, Schumacher A. A boostrap resampling procedure for model building: Application to the Cox regression model. Stat Med 1992; 11: 2093-109.
21. Osoba D, Rodrigues G, Myles J, Zee B, Pater J. I nterpreting the signifi cance of changes in health-related quality-of-life scores. J Clin Oncol 1998; 16: 139-44.
22. Butow P N, Coates A S, Dunn SM. P sychosocial predictors of survival in metastatic melanoma. J Clin Oncol 1999; 17: 2256-63.
23. Canada AL, Fawzy N W, Fawzy F I. P ersonality and disease outcome in malignant melanoma. J Psychosom Res 2005; 58: 19-27.
24. Lehto US, Ojanen M, Dyba T, Aromaa A, Kellokumpu-Lehtinen P. Baseline psychosocial predictors of survival in localized melanoma. J Psychosom Res 2007; 63: 9-15.
25. Bergenmar M, Nilsson B, Hansson J, Brandberg Y. A nxiety and depressive symptoms measured by the Hospital Anxiety and Depression Scale as predictors of time to recurrence in localized cutaneous melanoma. Acta Oncol 2004; 43: 161-8.
26. Brandberg Y, Mansson-Brahme E, Ringborg U, S jöd én PO. Psychological reactions in patients with malignant melanoma. Eur J Cancer 1995; 31A: 157-62.